diosgenin has been researched along with Non-alcoholic Fatty Liver Disease in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 3 (50.00) | 2.80 |
Authors | Studies |
---|---|
Gao, L; He, S; Jin, R; Lei, M; Li, Z; Peng, X; Shi, C; Wang, X; Yao, Y; Zhong, Y | 1 |
Chen, S; Dong, H; Fang, K; Gao, Y; Lu, F; Nie, K; Su, H; Tang, Y; Wang, H; Wang, Z | 1 |
Chen, S; Feng, Y; Li, X; Liang, P; Liu, H; Meng, D; Sun, S; Yin, G; Yu, W; Zhang, F; Zhang, X | 1 |
Chen, G; Dong, H; Fang, K; Li, J; Lu, F; Wu, F; Xu, L; Zhao, Y; Zou, X | 1 |
Cheng, B; Cheng, S; Deng, Z; Du, J; Li, S; Liang, S; Ling, C; Liu, Q; Zhang, Y | 1 |
Han, X; Peng, J; Qi, Y; Tao, X; Xu, L; Xu, Y; Yao, H; Yin, L; Zheng, L | 1 |
6 other study(ies) available for diosgenin and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Diosgenin; Fatty Acids; Lipogenesis; Liver; Mitochondria; Non-alcoholic Fatty Liver Disease; Rats | 2022 |
Diosgenin attenuates non-alcoholic fatty liver disease in type 2 diabetes through regulating SIRT6-related fatty acid uptake.
Topics: Animals; Diabetes Mellitus, Type 2; Diosgenin; Fatty Acids; Lipid Metabolism; Liver; Mice; Non-alcoholic Fatty Liver Disease; Sirtuins | 2023 |
Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARĪ±/CD36 pathway.
Topics: Animals; Diosgenin; Fatty Acids; Fatty Acids, Nonesterified; Liver; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1 | 2023 |
Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Carnitine O-Acetyltransferase; Cell Line; Diosgenin; Fatty Acid Synthases; Humans; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Signal Transduction; Sterol Regulatory Element Binding Protein 1 | 2019 |
Diosgenin prevents high-fat diet-induced rat non-alcoholic fatty liver disease through the AMPK and LXR signaling pathways.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Diosgenin; Hep G2 Cells; Humans; Hydrocarbons, Fluorinated; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Phosphorylation; Rats; Signal Transduction; Sulfonamides; Transcriptional Activation | 2018 |
Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Diosgenin; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Signal Transduction; Sirtuin 1 | 2018 |